Conecte-se

Bibliografias temáticas / Hematopoietic growth factors Therapeutic use / Artigos de revistas

Siga este link para ver outros tipos de publicações sobre o tema: Hematopoietic growth factors Therapeutic use.

Artigos de revistas sobre o tema "Hematopoietic growth factors Therapeutic use"

Autor: Grafiati

Publicado: 4 de junho de 2021

Última modificação: 1 de fevereiro de 2022

Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos

Selecione um tipo de fonte:

Veja os 50 melhores artigos de revistas para estudos sobre o assunto "Hematopoietic growth factors Therapeutic use".

Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.

Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.

Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.

1

Costa, John J. "The therapeutic use of hematopoietic growth factors." Journal of Allergy and Clinical Immunology 101, no. 1 (January 1998): 1–6. http://dx.doi.org/10.1016/s0091-6749(98)70185-x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

2

Sola, Martha, and Robert D. Christensen. "Use of Hematopoietic Growth Factors in the Neonatal Intensive Care Unit." Journal of Intensive Care Medicine 12, no. 4 (July 1997): 187–205. http://dx.doi.org/10.1177/088506669701200403.

Texto completo da fonte

Resumo:

Recombinant hematopoietic growth factors have emerged as valuable treatments for a variety of medical conditions. Recently, their applications have reached the neonatal intensive care unit, where they offer new therapeutic options for problems as common as anemia of prematurity, or as catastrophic as neonatal sepsis. When facing bacterial infection, it is known that newborn infants are capable of increasing their serum G-CSF concentrations. However, their response does not reach the concentrations that adults are able to achieve, and frequently neutropenia complicates the picture of neonatal s

Estilos ABNT, Harvard, Vancouver, APA, etc.

3

Bossi, Paolo, Cristina Gurizzan, Luigi Lorini, Pierluigi di Mauro, Chiara Sardini, and Marco Merlano. "Not all hematopoietic growth factors are created equal: should we gain information for their use with immunotherapy?" Journal for ImmunoTherapy of Cancer 9, no. 8 (August 2021): e003154. http://dx.doi.org/10.1136/jitc-2021-003154.

Texto completo da fonte

Resumo:

Myeloid growth factors, either granulocyte colony-stimulating factor (CSF) or granulocyte-macrophage CSF, are widely used to reduce the incidence and severity of chemotherapy-induced neutropenia by prophylactic or therapeutic administration. However, their activity in the novel therapeutic regimens, which often rely on the association between immunotherapy and chemotherapy, has not been thoroughly characterized yet. This paper presents some of the preclinical and clinical research regarding the putative interplay between myeloid growth factors and the immune system, advocating further studies

Estilos ABNT, Harvard, Vancouver, APA, etc.

4

Bridges, Sandra H., Margaret I. Johnston, and John J. McGowan. "Immunosuppression and HIV Infection: A Therapeutic Challenge." Canadian Journal of Infectious Diseases 3, suppl b (1992): 55–59. http://dx.doi.org/10.1155/1992/740587.

Texto completo da fonte

Resumo:

The optimal use of biological response modifiers (BRMs) in human immunodeficiency virus (HIV)-related disease depends on knowledge of the molecular basis of the immune deficiencies and dysregulations that occur during the course of the infection; evidence for the role of viral products and cytokines in the suppression of immune function is discussed. Immunebased therapies are currently being explored alone and in combination with drugs targeted to HIV and associated opportunistic infections and malignancies. These therapies include hematopoietic growth factors for the management of drug toxici

Estilos ABNT, Harvard, Vancouver, APA, etc.

5

Siena, Salvatore, Roberta Schiavo, Paolo Pedrazzoli, and Carmelo Carlo-Stella. "Therapeutic Relevance of CD34 Cell Dose in Blood Cell Transplantation for Cancer Therapy." Journal of Clinical Oncology 18, no. 6 (March 13, 2000): 1360–77. http://dx.doi.org/10.1200/jco.2000.18.6.1360.

Texto completo da fonte

Resumo:

PURPOSE: To review recent advances in peripheral-blood progenitor-cell (PBPC) transplantation in order to define the optimal cell dose required for autologous and allogeneic transplantation. MATERIALS AND METHODS: A search of MEDLINE was conducted to identify relevant publications. Their bibliographies were also used to identify further articles and abstracts for critical review. RESULTS: The CD34+ cell content of a graft is regarded as an accurate predictor of engraftment success. Postchemotherapy autologous PBPC transplantation with ≥ 5 × 106 CD34+ cells/kg body weight leads to more rapid en

Estilos ABNT, Harvard, Vancouver, APA, etc.

6

Zhao, Q., X. Song, T. Waldschmidt, E. Fisher, and AM Krieg. "Oligonucleotide uptake in human hematopoietic cells is increased in leukemia and is related to cellular activation." Blood 88, no. 5 (September 1, 1996): 1788–95. http://dx.doi.org/10.1182/blood.v88.5.1788.1788.

Texto completo da fonte

Resumo:

Abstract The use of antisense oligonucleotides as tools for modulating gene expression represents a novel strategy for designing drugs to treat a variety of diseases. Several factors, including cellular uptake and internalization of the oligonucleotides, are important parameters in determining the effectiveness of antisense agents such as therapeutic drugs. We have studied oligonucleotides uptake in normal and leukemic human hematopoietic cells, such as peripheral blood, bone marrow (BM), and HL-60 cell line; and have found that, in normal human blood and BM, myeloid cells and B cells preferab

Estilos ABNT, Harvard, Vancouver, APA, etc.

7

Zhao, Q., X. Song, T. Waldschmidt, E. Fisher, and AM Krieg. "Oligonucleotide uptake in human hematopoietic cells is increased in leukemia and is related to cellular activation." Blood 88, no. 5 (September 1, 1996): 1788–95. http://dx.doi.org/10.1182/blood.v88.5.1788.bloodjournal8851788.

Texto completo da fonte

Resumo:

The use of antisense oligonucleotides as tools for modulating gene expression represents a novel strategy for designing drugs to treat a variety of diseases. Several factors, including cellular uptake and internalization of the oligonucleotides, are important parameters in determining the effectiveness of antisense agents such as therapeutic drugs. We have studied oligonucleotides uptake in normal and leukemic human hematopoietic cells, such as peripheral blood, bone marrow (BM), and HL-60 cell line; and have found that, in normal human blood and BM, myeloid cells and B cells preferably took u

Estilos ABNT, Harvard, Vancouver, APA, etc.

8

Thaker, Hatim, and Arun K. Sharma. "Engaging Stem Cells for Customized Tendon Regeneration." Stem Cells International 2012 (2012): 1–12. http://dx.doi.org/10.1155/2012/309187.

Texto completo da fonte

Resumo:

The need for a consistent therapeutic approach to tendon injury repair is long overdue. Patients with tendon microtears or full ruptures are eligible for a wide range of invasive and non invasive interventions, often subjectively decided by the physician. Surgery produces the best outcomes, and while studies have been conducted to optimize graft constructs and to track outcomes, the data from these studies have been inconclusive on the whole. What has been established is a clear understanding of healthy tendon architecture and the inherent process of healing. With this knowledge, tissue regene

Estilos ABNT, Harvard, Vancouver, APA, etc.

9

Mohindru, Mani, Perry Pahanish, Efstratios Katsoulidis, Robert Collins, Thomas Rogers, Tony Navas, Linda Higgins, Leonidas Platanias, and Amit Verma. "Novel P38 MAP Kinase Inhibitor and Anti-P38 RNA Interference as Potential Therapeutic Approaches in Myelodysplastic Syndromes." Blood 104, no. 11 (November 16, 2004): 470. http://dx.doi.org/10.1182/blood.v104.11.470.470.

Texto completo da fonte

Resumo:

Abstract Cytokines such as TNF α, IFN γ and others have been implicated in the pathogenesis of ineffective hematopoiesis in MDS and are thought to lead to the high rate of apoptosis in hematopoietic progenitors. The p38 Mitogen Activated Protein Kinase (MAPK) is an evolutionary conserved enzyme that is involved in many cellular processes including stress signaling. We have previously shown that the p38 MAP kinase is strongly activated by IFNs, TNF α, TGF β and other inhibitory cytokines in normal primary hematopoietic progenitors and plays an important role in the negative regulation of normal

Estilos ABNT, Harvard, Vancouver, APA, etc.

10

Or, Reuven, Sigal Grisaro, Batia Ronit Avni, Igor Resnick, Lilyan Dari, David Shoshani, Dalia Bracha, Nurit Beilin, Limor Lior, and Michael Y. Shapira. "Correction of Post-Transplant Hematopoiesis by Novel Use of Mesenchymal-Like Placental Expanded Cells (PLX) Administered Intra-Muscular." Blood 120, no. 21 (November 16, 2012): 4133. http://dx.doi.org/10.1182/blood.v120.21.4133.4133.

Texto completo da fonte

Resumo:

Abstract Abstract 4133 Post autologous or allogeneic stem cell transplantation hematopoietic dysfunction is a common phenomenon caused by multiple factors. Complicating the treatment of this condition is the fact that additional reserves of stem cells for autologous transplantation is usually unavailable and the use of allogeneic stem cells, if available, may be associated with transplant related complications, including graft versus host disease. Furthermore, the addition of donor cells may be ineffective because the underlying disease may also damage the supplemented stem cells. Prolonged pa

Estilos ABNT, Harvard, Vancouver, APA, etc.

11

Coman, Tereza, Guillemette Fouquet, Julien Rossignol, Jean-Henri Bourhis, Olivier Hermine, and Francine Côté. "Serotonin Targeting Using Common Antidepressants Induces Rapid Recovery of Cytopenia." Blood 134, Supplement_1 (November 13, 2019): 3715. http://dx.doi.org/10.1182/blood-2019-122658.

Texto completo da fonte

Resumo:

Background. Hematopoiesis is a highly regulated system where multiple, yet undiscovered, factors orchestrate the self-renewal of bone marrow stem cells and their differentiation into blood cells. Following acute stresses like infections, inflammation, chemotherapy or radiation, the hematopoietic system quickly adapts by a process termed "emergency" or "stress" hematopoiesis. For instance, switches from steady state to emergency granulopoiesis or emergency erythropoiesis have been described in response to infection or bleeding. We recently identified, both in human and murine erythroid progenit

Estilos ABNT, Harvard, Vancouver, APA, etc.

12

Papanikolaou, Xenofon Dimitrios, Eric Rosenbaum, Lisa Tyler, Bart Barlogie, and Michele Cottler-Fox. "Factors that predict successful remobilization after autologous hematopoietic progenitor cell transplant (aHCT) for multiple myeloma." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 8610. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.8610.

Texto completo da fonte

Resumo:

8610 Background: aHCT is a proven therapeutic modality in treating relapsed multiple myeloma (MM). However, previously transplanted patients may have no hematopoietic progenitor cells (HPC) left in storage. Methods: Collection of HPC after aHCT was studied in 221 MM patients who underwent 333 mobilization attempts between 10/2000 and 06/2012. Results: The median number of CD34+ collected was 4.7 ×106/kg, with 74% of collections yielding at least 2.5×106/kg. Mobilization with chemotherapy and G-CSF was most efficient, yielding a median of 6.84×106/kg (p<0.001). Growth factor-only mobilizatio

Estilos ABNT, Harvard, Vancouver, APA, etc.

13

Brugger, W., W. Mocklin, S. Heimfeld, RJ Berenson, R. Mertelsmann, and L. Kanz. "Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin." Blood 81, no. 10 (May 15, 1993): 2579–84. http://dx.doi.org/10.1182/blood.v81.10.2579.2579.

Texto completo da fonte

Resumo:

Abstract To provide sufficient numbers of peripheral blood progenitor cells (PBPCs) for repetitive use after high-dose chemotherapy, we investigated the ability of hematopoietic growth factor combinations to expand the number of clonogenic PBPCs ex vivo. Chemotherapy plus granulocyte colony-stimulating factor (G-CSF) mobilized CD34+ cells from 18 patients with metastatic solid tumors or refractory lymphomas were cultured for up to 28 days in a liquid culture system. The effects of interleukin-1 beta (IL-1), IL-3, IL-6, granulocyte-macrophage-CSF (GM-CSF), G-CSF, macrophage-CSF (M-CSF), stem ce

Estilos ABNT, Harvard, Vancouver, APA, etc.

14

Brugger, W., W. Mocklin, S. Heimfeld, RJ Berenson, R. Mertelsmann, and L. Kanz. "Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin." Blood 81, no. 10 (May 15, 1993): 2579–84. http://dx.doi.org/10.1182/blood.v81.10.2579.bloodjournal81102579.

Texto completo da fonte

Resumo:

To provide sufficient numbers of peripheral blood progenitor cells (PBPCs) for repetitive use after high-dose chemotherapy, we investigated the ability of hematopoietic growth factor combinations to expand the number of clonogenic PBPCs ex vivo. Chemotherapy plus granulocyte colony-stimulating factor (G-CSF) mobilized CD34+ cells from 18 patients with metastatic solid tumors or refractory lymphomas were cultured for up to 28 days in a liquid culture system. The effects of interleukin-1 beta (IL-1), IL-3, IL-6, granulocyte-macrophage-CSF (GM-CSF), G-CSF, macrophage-CSF (M-CSF), stem cell factor

Estilos ABNT, Harvard, Vancouver, APA, etc.

15

Melo, Adriana de, André Luiz de Melo, Maria Cristina Marcucci, Claudemir de Carvalho, and Carolina Passarelli Gonçalves. "Immunomodulatory activity in tumor-bearing mice treated with Withania somnifera extract." Journal of Analytical & Pharmaceutical Research 10, no. 2 (April 12, 2021): 82–91. http://dx.doi.org/10.15406/japlr.2021.10.00369.

Texto completo da fonte

Resumo:

We investigated some actions of Withania somnifera on the growth and differentiation of hematopoietic precursors [granulocyte/macrophage colony cell formation (CFU-GM)] of normal animals and EAT bearers, which were treated with different doses (20, 50, or 100 mg/kg/day). We also evaluated the presence of colony stimulatory factors in the animal's serum, as well as its survival. Furthermore, we analyzed lymphocyte proliferation, IFN-ɤ, and TNF-α concentrations in treated bearing mice. Our results demonstrated Withania somnifera effectiveness on hematopoietic precursors growth and differentiatio

Estilos ABNT, Harvard, Vancouver, APA, etc.

16

Haritwal, Teena, Noopur Gupta, Mrinalini Tiwari, Sarvesh Surve, and Paban Kumar Agrawala. "Radiation Countermeasures: Current Status." Defence Life Science Journal 2, no. 3 (August 3, 2017): 278. http://dx.doi.org/10.14429/dlsj.2.11675.

Texto completo da fonte

Resumo:

Deleterious effects of ionising radiation leading to significant morbidity and mortality have been studied elaborately. A range of synthetic, semisynthetic and herbal compounds have been screened as radiation countermeasure agents and a number of promising radiation countermeasure agents are under development. Amifostin is the only drug which has been approved by the United State Food and Drug Administration (US-FDA), but that too for use in a defined population under strict medical supervision. Granulocyte Colony Stimulating Factor/filgrastim, γ-tocotrienol, genistein are at an advanced stage

Estilos ABNT, Harvard, Vancouver, APA, etc.

17

Logothetis, C. J., L. D. Finn, T. Smith, R. G. Kilbourn, J. A. Ellerhorst, A. A. Zukiwski, A. Sella, S. M. Tu, and R. J. Amato. "Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial." Journal of Clinical Oncology 13, no. 9 (September 1995): 2272–77. http://dx.doi.org/10.1200/jco.1995.13.9.2272.

Texto completo da fonte

Resumo:

PURPOSE Hematopoietic growth factors have been shown to ameliorate the side effects of chemotherapy. Here we assess the ability of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) to increase the dose-intensity and reduce the side effects of escalated methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy. PATIENTS AND METHODS A prospective randomized trial to compare escalated MVAC versus escalated MVAC with rhGM-CSF was conducted. All patients were treated at The University of Texas M.D. Anderson Cancer Center (UTMDACC) and had a metastatic or

Estilos ABNT, Harvard, Vancouver, APA, etc.

18

Goncharova, Valentina, Ingrid U. Schraufstaetter, Shinji Iizuka, Yu Yamaguchi, and Sophia K. Khaldoyanidi. "Hyaluronan Expressed by Bone Marrow Mesenchymal Cells Regulates Functions of the Hematopoietic Microenvironment." Blood 120, no. 21 (November 16, 2012): 1243. http://dx.doi.org/10.1182/blood.v120.21.1243.1243.

Texto completo da fonte

Resumo:

Abstract Abstract 1243 While the quantity and quality of transplanted hematopoietic stem cells (HSC) are important for the recovery of hematopoiesis, the functional status of the regulatory hematopoietic microenvironment is a critical parameter that determines the regenerative function of HSCs. The quality of the microenvironment, i.e. its ability to support hematopoiesis, may be compromised under pathological circumstances such as during disease development or as a result of therapeutic interventions. Thus, the hematopoietic microenvironment should be allowed to recover prior to HSC transplan

Estilos ABNT, Harvard, Vancouver, APA, etc.

19

Kohrogi, Kensaku, Shinjiro Hino, Akihisa Sakamoto, Kotaro Anan, Ryuta Takase, Hirotaka Araki, Yuko Hino та ін. "LSD1 defines erythroleukemia metabolism by controlling the lineage-specific transcription factors GATA1 and C/EBPα". Blood Advances 5, № 9 (30 квітня 2021): 2305–18. http://dx.doi.org/10.1182/bloodadvances.2020003521.

Texto completo da fonte

Resumo:

Abstract Acute myeloid leukemia (AML) is a heterogenous malignancy characterized by distinct lineage subtypes and various genetic/epigenetic alterations. As with other neoplasms, AML cells have well-known aerobic glycolysis, but metabolic variations depending on cellular lineages also exist. Lysine-specific demethylase-1 (LSD1) has been reported to be crucial for human leukemogenesis, which is currently one of the emerging therapeutic targets. However, metabolic roles of LSD1 and lineage-dependent factors remain to be elucidated in AML cells. Here, we show that LSD1 directs a hematopoietic lin

Estilos ABNT, Harvard, Vancouver, APA, etc.

20

Basu, Sunanda, and Hal E. Broxmeyer. "Role of Integrin Linked Kinase in Expansion and Chemotaxis of CD34+ Cord Blood Cells." Blood 114, no. 22 (November 20, 2009): 3616. http://dx.doi.org/10.1182/blood.v114.22.3616.3616.

Texto completo da fonte

Resumo:

Abstract 3616 Poster Board III-552 Despite being an excellent alternative to bone marrow or mobilized peripheral blood as a source of hematopoietic stem progenitor cells (HSPCs), the limiting factor to wider use of cord blood (CB) in transplantation is the 10-fold lower cell dose in a typical CB unit compared to harvested bone marrow or peripheral blood stem cells. Successful ex-vivo expansion of HSPCs as well as increasing transplantation efficiency by adopting protocols that enhance homing and engraftment of transplanted HSPC provides hope of making the applicability of a single unit of CB w

Estilos ABNT, Harvard, Vancouver, APA, etc.

21

Pleimes, Dirk, Vivienne Bunker, Michael Meyer, and Maciej Czajkowski. "Effects of a Novel Orally Bioavailable Small Molecule (Imidazolyl Ethanamide Pentandioic Acid) on Acute Radiation Syndrome." Blood 132, Supplement 1 (November 29, 2018): 5089. http://dx.doi.org/10.1182/blood-2018-99-114490.

Texto completo da fonte

Resumo:

Abstract Introduction Acute radiation syndrome (ARS) develops within 24 hours of exposure to ionizing radiation. Leukocyte growth factors have been used to reduce mortality and mitigate the hematopoietic symptoms of ARS. Three subcutaneously applied radiomitigators G-CSF, Peg-G-CSF and GM-CSF have been approved by the FDA as medical countermeasures but few others are under development. Imidazolyl ethanamide pentandioic acid (IEPA, Myelo001) is a novel small molecule for the treatment of ARS. Preclinical and clinical studies have shown that IEPA applied orally or intraperitoneally was effective

Estilos ABNT, Harvard, Vancouver, APA, etc.

22

Kalra, R., D. Dale, M. Freedman, MA Bonilla, M. Weinblatt, A. Ganser, P. Bowman, S. Abish, J. Priest, and RS Oseas. "Monosomy 7 and activating RAS mutations accompany malignant transformation in patients with congenital neutropenia." Blood 86, no. 12 (December 15, 1995): 4579–86. http://dx.doi.org/10.1182/blood.v86.12.4579.bloodjournal86124579.

Texto completo da fonte

Resumo:

Individuals with severe forms of congenital neutropenia suffer from recurrent infections. The therapeutic use of recombinant human granulocyte colony-stimulating factor (rhG-CSF) to increase the neutrophil count is associated with fewer infections and an improved quality of life. However, the long-term effects of this new therapy are largely unknown. In particular, it is unclear if myeloid leukemia, a known complication of some forms of congenital neutropenia, will occur with increased frequency among patients who receive long-term treatment with hematopoietic growth factors. We report 13 pati

Estilos ABNT, Harvard, Vancouver, APA, etc.

23

Tabayashi, Takayuki, Yasuyuki Takahashi, Yuta Kimura, Tatsuki Tomikawa, Morihiko Sagawa, Tomoe Nemoto, Reiko Watanabe, Michihide Tokuhira, Shigehisa Mori та Masahiro Kizaki. "Targeting the Wnt/β-Catenin Signaling Pathway in Multiple Myeloma: A Possible New Therapeutic Approach to Overcome Bortezomib-Resistance". Blood 124, № 21 (6 грудня 2014): 3372. http://dx.doi.org/10.1182/blood.v124.21.3372.3372.

Texto completo da fonte

Resumo:

Abstract Multiple myeloma (MM) is a neoplasm of plasma cells that is often fatal, despite the use of high dose chemotherapy and hematopoietic stem cell transplantation. Although new therapeutic approaches, including novel agents such as thalidomide, lenalidomide, and bortezomib (a proteasome inhibitor), are now used clinically and have improved the outcome of patients with MM, most patients eventually relapse, and it remains an incurable disease. Wnt/β-catenin signaling plays a critical role in both cell proliferation and differentiation in normal tissue. β-catenin, a key player and downstream

Estilos ABNT, Harvard, Vancouver, APA, etc.

24

Singh, Pratibha, Seiji Fukuda, Mary R. Saunders, and Louis M. Pelus. "Survivin Is a Master Regulator of Mesenchymal Stem Cell Functions and Potential Therapeutic Target for Mesenchymal Stem Cell Expansion." Blood 124, no. 21 (December 6, 2014): 774. http://dx.doi.org/10.1182/blood.v124.21.774.774.

Texto completo da fonte

Resumo:

Mesenchymal stemcells (MSCs) are found throughout adult organisms and are involved in tissue maintenance and repair, as well as in the regulation of hematopoiesis and immunologic responses. Several clinical trials are currently under way to use allogeneic MSCs for enhancement of hematopoietic stem cell transplantation and treatment of graft-versus-host disease, spinal cord injury, cartilage and meniscus repair, and stroke. However, the therapeutic uses of MSCs can be limited by insufficient MSC number, their survival, and their ability to differentiate into multiple lineages, pointing to an im

Estilos ABNT, Harvard, Vancouver, APA, etc.

25

Löwenberg, B., M. A. Boogaerts, S. M. Daenen, G. E. Verhoef, A. Hagenbeek, E. Vellenga, G. J. Ossenkoppele, et al. "Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia." Journal of Clinical Oncology 15, no. 12 (December 1997): 3496–506. http://dx.doi.org/10.1200/jco.1997.15.12.3496.

Texto completo da fonte

Resumo:

PURPOSE The hematopoietic growth factors (HGFs) introduced into induction chemotherapy (CT) of acute myeloid leukemia (AML) might be of benefit to treatment outcome by at least two mechanisms. HGFs given on days simultaneously with CT might sensitize the leukemic cells and enhance their susceptibility to CT. HGFs applied after CT might hasten hematopoietic recovery and reduce morbidity or mortality. MATERIALS AND METHODS We set out to evaluate the use of granulocyte-macrophage colony-stimulating factor (GM-CSF; 5 microg/kg) in a prospective randomized study of factorial design (yes or no GM-CS

Estilos ABNT, Harvard, Vancouver, APA, etc.

26

Nowak, Witold N., Hevidar Taha, Joanna Markiewicz, Neli Kachamakova-Trojanowska, Jacek Stępniewski, Damian Klóska, Urszula Florczyk-Soluch, et al. "Atorvastatin and Conditioned Media from Atorvastatin-Treated Human Hematopoietic Stem/Progenitor-Derived Cells Show Proangiogenic Activity In Vitro but Not In Vivo." Mediators of Inflammation 2019 (July 16, 2019): 1–15. http://dx.doi.org/10.1155/2019/1868170.

Texto completo da fonte

Resumo:

Myeloid angiogenic cells (MAC) derive from hematopoietic stem/progenitor cells (HSPCs) that are mobilized from the bone marrow. They home to sites of neovascularization and contribute to angiogenesis by production of paracrine factors. The number and function of proangiogenic cells are impaired in patients with diabetes or cardiovascular diseases. Both conditions can be accompanied by decreased levels of heme oxygenase-1 (HMOX1), cytoprotective, heme-degrading enzyme. Our study is aimed at investigating whether precursors of myeloid angiogenic cells (PACs) treated with known pharmaceuticals wo

Estilos ABNT, Harvard, Vancouver, APA, etc.

27

Majka, Marcin, Magdalena Kucia, and Mariusz Z. Ratajczak. "Stem cell biology: a never ending quest for understanding." Acta Biochimica Polonica 52, no. 2 (June 25, 2005): 353–58. http://dx.doi.org/10.18388/abp.2005_3448.

Texto completo da fonte

Resumo:

Stem cells (SC) research is an important part of biotechnology that could lead to the development of new therapeutic strategies. A lot of effort has been put to understand biology of the stem cells and to find genes and subsequently proteins that are responsible for their proliferation, self-renewal and differentiation. Different cytokines and growth factors has been used to expand stem cells, but no combination of these factors was identified that could effectively expand the most primitive stem cells. Recently, however, genes and receptors responsible for SC proliferation and differentiation

Estilos ABNT, Harvard, Vancouver, APA, etc.

28

Bashirov, Farid V., Ilnur I. Salafutdinov, Michail E. Sokolov, Andrew A. Izmailov, Vage A. Markosyan, Filip O. Fadeev, Albert Rizvanov, and Rustem I. Islamov. "Umbilical Cord Blood Mononuclear Cells for Ex-Vivo Gene Therapy." Blood 132, Supplement 1 (November 29, 2018): 5797. http://dx.doi.org/10.1182/blood-2018-99-113462.

Texto completo da fonte

Resumo:

Abstract Cell-mediated (ex-vivo) gene therapy for the treatment of adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID) had started in 1990 and nowadays it is the first marketing approval of an ex vivo gene therapy in Europe. The method based on ex-vivo transduction of peripheral blood lymphocytes with retroviral vector carrying the functional ADA gene in 2002 have been improved to use hematopoietic stem cell (HSC) for ex-vivo transduction with 100% survival and the evidence of safety and efficacy. Remarkably, umbilical cord blood mononuclear cells (UCB-MC) were successf

Estilos ABNT, Harvard, Vancouver, APA, etc.

29

Dighe, Niraja, Subhashree Venkatesan, Poon Zhiyong, and William YK Hwang. "Mechanism of Action of Azacytidine in Myelodysplastic Syndromes (MDS)." Blood 128, no. 22 (December 2, 2016): 4315. http://dx.doi.org/10.1182/blood.v128.22.4315.4315.

Texto completo da fonte

Resumo:

Abstract Introduction: Myelodysplastic syndromes (MDS) have historically been classified as a set of heterogeneous hematopoietic stem cell (HSC) disorders, which are characterized clinically by abnormalities in the hematopoietic system. However, several recent landmark studies have now demonstrated that the pathogenesis of MDS is not confined to HSCs, and mesenchymal stromal cells (MSCs) in the bone marrow also play important contributing roles in sustaining the disorder. Treatment for MDS using hypomethylating agents such as azacytidine is effective, with patients showing recovery of blood co

Estilos ABNT, Harvard, Vancouver, APA, etc.

30

Kruger, Ryan G., Helai Mohammad, Kimberly Smitheman, Monica Cusan, Yan Liu, Melissa Pappalardi, Kelly Federowicz, et al. "Inhibition Of LSD1 As a Therapeutic Strategy For The Treatment Of Acute Myeloid Leukemia." Blood 122, no. 21 (November 15, 2013): 3964. http://dx.doi.org/10.1182/blood.v122.21.3964.3964.

Texto completo da fonte

Resumo:

Abstract Lysine specific demethylase 1 (LSD1) is a histone H3K4me1/2 demethylase found in various transcriptional co-repressor complexes. These complexes include Histone Deacetylases (HDAC1/2) and Co-Repressor for Element-1-Silencing Transcription factor (CoREST). LSD1 mediated H3K4 demethylation can result in a repressive chromatin environment that silences gene expression. LSD1 has been shown to play a role in development in various contexts. LSD1 can interact with pluripotency factors in human embryonic stem cells and is important for decommissioning enhancers in stem cell differentiation.

Estilos ABNT, Harvard, Vancouver, APA, etc.

31

Thompson, Zanshe, Melanie Rodriguez, Georgina Anderson, Seth Gabriel, Vera Binder, Leonard I. Zon, and Katie L. Kathrein. "Ing4 Suppresses Quiescence and Inflammation in Hematopoietic Stem Cells." Blood 136, Supplement 1 (November 5, 2020): 16. http://dx.doi.org/10.1182/blood-2020-143388.

Texto completo da fonte

Resumo:

Hematopoietic stem and progenitor cell (HSPC) development and maintenance is regulated through a complex regulatory network. In a screen of epigenetic regulators of hematopoiesis in zebrafish, we identified a requirement for the tumor suppressor protein, Inhibitor of growth 4 (Ing4) in HSPC specification. Ing4 acts to regulate transcription through interactions with transcription factors, including HIF, NF-kB, and p53. It is often mis-expressed in many human cancers and has been shown to promote stem cell-like characteristics in malignant cells, in part, due to the inhibitory role of Ing4 in t

Estilos ABNT, Harvard, Vancouver, APA, etc.

32

DONAHUE, ROBERT E., STEVEN C. CLARK, and ROBERT KAMEN. "Hematopoietic Growth Factors as Therapeutic Agents." Annals of the New York Academy of Sciences 511, no. 1 Normal and Ne (December 1987): 10–16. http://dx.doi.org/10.1111/j.1749-6632.1987.tb36233.x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

33

Estrov, Z., R. Kurzrock, M. Wetzler, H. Kantarjian, M. Blake, D. Harris, JU Gutterman, and M. Talpaz. "Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity." Blood 78, no. 6 (September 15, 1991): 1476–84. http://dx.doi.org/10.1182/blood.v78.6.1476.1476.

Texto completo da fonte

Resumo:

Abstract In this study, we investigated the role of interleukin-1 beta (IL-1 beta) in the malignant evolution of chronic myelogenous leukemia (CML) and the functional activity of IL-1 inhibitors. Bone marrow (BM) and peripheral blood (PB) low-density cells from 38 CML patients were studied in the colony-forming unit-granulocyte, erythrocyte, monocyte, megakaryocyte colony culture assay. Samples from patients with early stage, interferon-alpha (IFN)-sensitive disease formed hematopoietic colonies in the presence of fetal calf serum (FCS), erythropoietin (Epo), and one of the following: granuloc

Estilos ABNT, Harvard, Vancouver, APA, etc.

34

Estrov, Z., R. Kurzrock, M. Wetzler, H. Kantarjian, M. Blake, D. Harris, JU Gutterman, and M. Talpaz. "Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity." Blood 78, no. 6 (September 15, 1991): 1476–84. http://dx.doi.org/10.1182/blood.v78.6.1476.bloodjournal7861476.

Texto completo da fonte

Resumo:

In this study, we investigated the role of interleukin-1 beta (IL-1 beta) in the malignant evolution of chronic myelogenous leukemia (CML) and the functional activity of IL-1 inhibitors. Bone marrow (BM) and peripheral blood (PB) low-density cells from 38 CML patients were studied in the colony-forming unit-granulocyte, erythrocyte, monocyte, megakaryocyte colony culture assay. Samples from patients with early stage, interferon-alpha (IFN)-sensitive disease formed hematopoietic colonies in the presence of fetal calf serum (FCS), erythropoietin (Epo), and one of the following: granulocyte-macro

Estilos ABNT, Harvard, Vancouver, APA, etc.

35

Kumar, Narendra, Longxiang Kuang, Ryan Villa, Priyam Kumar, and Jayshree Mishra. "Mucosal Epithelial Jak Kinases in Health and Diseases." Mediators of Inflammation 2021 (March 16, 2021): 1–17. http://dx.doi.org/10.1155/2021/6618924.

Texto completo da fonte

Resumo:

Janus kinases (Jaks) are a family of nonreceptor tyrosine kinase that include four different members, viz., Jak1, Jak2, Jak3, and Tyk2. Jaks play critical roles in immune cells functions; however, recent studies suggest they also play essential roles in nonimmune cell physiology. This review highlights the significance of epithelial Jaks in understanding the molecular basis of some of the diseases through regulation of epithelial-mesenchymal transition, cell survival, cell growth, development, and differentiation. Growth factors and cytokines produced by the cells of hematopoietic origin use J

Estilos ABNT, Harvard, Vancouver, APA, etc.

36

Nii, Takenobu, Tomotoshi Marumoto, Hirotaka Kawano, Saori Yamaguchi, Yoko Nagai, Jiyuan Liao, Michiyo Okada, Yoshie Miura, and Kenzaburo Tani. "Efficient Hematopoietic Differentiation of Common Marmoset Embryonic Stem Cells by the Inhibition of Their Self-Renewal Pathway." Blood 120, no. 21 (November 16, 2012): 2311. http://dx.doi.org/10.1182/blood.v120.21.2311.2311.

Texto completo da fonte

Resumo:

Abstract Abstract 2311 The human regenerative medicine by the transplantation of the functional cells differentiated from embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) have great potential of contributing to the treatments for various diseases, and thus have attracted huge public attention. However, the risk of unwelcome tumor formation originated from transplanted cells in recipients remains to be solved. Therefore the safety and efficacy of ESC/iPSC-based therapies should be carefully evaluated using reliable animal disease models before their clinical application. Am

Estilos ABNT, Harvard, Vancouver, APA, etc.

37

Ganser, Arnold, and Meinolf Karthaus. "Clinical use of hematopoietic growth factors." Current Opinion in ONCOLOGY 8, no. 4 (July 1996): 265–69. http://dx.doi.org/10.1097/00001622-199607000-00001.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

38

Sunthankar, Kathryn I., Benjamin J. Reisman, Candace H. Cote, and Paul Brent Ferrell. "Single Cell Signaling Responses Stratify Immune and Leukemia Cell Populations in Acute Myeloid Leukemia." Blood 134, Supplement_1 (November 13, 2019): 2680. http://dx.doi.org/10.1182/blood-2019-129602.

Texto completo da fonte

Resumo:

In healthy hematopoiesis, cell identity and signaling response are tightly linked, with predictable cell type-specific responses to cytokines and growth factors. However, this correlation is often disrupted in myeloid malignancies, including acute myeloid leukemia (AML), wherein signaling responses may be driven directly by kinase mutational activation or cell state changes due to epigenetic alterations, for instance. In order to resolve ligand-driven signaling pathways in bone marrow, tools that allow simultaneous phenotypic characterization and functional cellular responses at single cell re

Estilos ABNT, Harvard, Vancouver, APA, etc.

39

Waldmann, Thomas A., Ronald Levy, and Barry S. Coller. "Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy." Hematology 2000, no. 1 (January 1, 2000): 394–408. http://dx.doi.org/10.1182/asheducation.v2000.1.394.20000394.

Texto completo da fonte

Resumo:

This article focuses on the recent dramatic advances in the applications of monoclonal antibody therapy to hematopoietic and neoplastic disease. The increase in the understanding of the role of growth factors and their receptors in the pathogenesis of malignancy and other undesirable hematological events taken in conjunction with the ability to produce humanized chimeric monoclonal antibodies to these targets is providing a new perspective for the treatment of leukemia, lymphoma and breast cancer, autoimmune disease and for prevention of ischemic complications. Dr. Waldmann describes approache

Estilos ABNT, Harvard, Vancouver, APA, etc.

40

Waldmann, Thomas A., Ronald Levy, and Barry S. Coller. "Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy." Hematology 2000, no. 1 (January 1, 2000): 394–408. http://dx.doi.org/10.1182/asheducation.v2000.1.394.394.

Texto completo da fonte

Resumo:

Abstract This article focuses on the recent dramatic advances in the applications of monoclonal antibody therapy to hematopoietic and neoplastic disease. The increase in the understanding of the role of growth factors and their receptors in the pathogenesis of malignancy and other undesirable hematological events taken in conjunction with the ability to produce humanized chimeric monoclonal antibodies to these targets is providing a new perspective for the treatment of leukemia, lymphoma and breast cancer, autoimmune disease and for prevention of ischemic complications. Dr. Waldmann describes

Estilos ABNT, Harvard, Vancouver, APA, etc.

41

Rowe, A., J. Eberhard, and J. Sanchez-Ramos. "Hematopoietic growth factors: Novel therapeutic strategy for Alzheimer's disease." Drugs of the Future 34, no. 12 (2009): 977. http://dx.doi.org/10.1358/dof.2009.034.12.1416991.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

42

Hayakawa, Fumihiko, Keiki Sugimoto, Shingo Kurahashi, Hironori Matsuyama, Yasuo Harada, Norikazu Hashimoto, Naoto Ohi, et al. "A Novel Direct STAT3 Inhibitor OPB-31121 Induces Tumor-Specific Growth Inhibition In a Wide Range of Hematopoietic Malignancies and Effectively Suppresses the Chemotherapy Resistant Quiescent Cells In Vivo." Blood 116, no. 21 (November 19, 2010): 3277. http://dx.doi.org/10.1182/blood.v116.21.3277.3277.

Texto completo da fonte

Resumo:

Abstract Abstract 3277 Signal Transduction and Activator of Transcription (STAT) proteins are extracellular ligand-responsive transcription factors that mediate a wide range of biological processes such as cell proliferation, apoptosis, differentiation, development, and immune response. Stimulation with cytokines or growth factors results in the tyrosine phosphorylation of STAT proteins via activation of upstream tyrosine kinases like Janus kinase (JAK) family kinases. Activated STAT proteins translocate to the nucleus and regulate gene expression through direct binding to the promoters of res

Estilos ABNT, Harvard, Vancouver, APA, etc.

43

Merchan Ruiz, Brayan Marcel, Teresa Bernal, Montserrat Arnan, Mar Tormo, Jose Angel Hernandez Rivas, Maria Calbacho, Rosa Coll, et al. "IMPACT of Therapeutic Strategy and Time to Therapy Initiation on Clinical Evolution of Patients with NEWLY Diagnosed Chronic Myelomonocytic Leukemia. a Report from Erasme Study." Blood 124, no. 21 (December 6, 2014): 5607. http://dx.doi.org/10.1182/blood.v124.21.5607.5607.

Texto completo da fonte

Resumo:

Abstract Introduction Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder characterized by a heterogeneous clinical and morphological expression that shares features of both myelodysplastic syndromes (MDS) and chronic myeloproliferative disorders. In the last years therapy of CMML has undergone a change with the inclusion of the demethylating agents but data regarding their impact on the “real life” setting are still scarce. The aim of our study was to evaluate the use of the different therapies and the time to therapy in an unselected Spanish population within

Estilos ABNT, Harvard, Vancouver, APA, etc.

44

Xie, Jingjing, Zhigang Lu, and Chengcheng Zhang. "KBP-1 Supports Acute Myeloid Leukemia Development." Blood 126, no. 23 (December 3, 2015): 1378. http://dx.doi.org/10.1182/blood.v126.23.1378.1378.

Texto completo da fonte

Resumo:

Abstract Novel targets are needed to develop effective therapeutic approaches to treat acute myeloid leukemia (AML). We have developed a systematic strategy to identify factors important for leukemia development. We first use clinical databases to identify plasma membrane proteins that have correlations with the clinical outcomes of leukemia patients. We then validate the functions of candidate proteins in leukemia models and compare these functions to those in normal cells. The signaling pathways identified provide candidate targets for development of therapeutic approaches. Using this approa

Estilos ABNT, Harvard, Vancouver, APA, etc.

45

Nemunaitis, John. "Use of hematopoietic growth factors in marrow transplantation." Current Opinion in Oncology 6, no. 2 (March 1994): 139–46. http://dx.doi.org/10.1097/00001622-199403000-00005.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

46

&NA;. "Clinical use of hematopoietic growth factors and myelosuppression." Current Opinion in ONCOLOGY 8, no. 4 (July 1996): B105–113. http://dx.doi.org/10.1097/00001622-199607000-00013.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

47

Gale, Robert Peter, and Anna Butturini. "Use of hematopoietic growth factors in radiation accidents." International Journal of Radiation Oncology*Biology*Physics 19, no. 5 (November 1990): 1291–95. http://dx.doi.org/10.1016/0360-3016(90)90247-h.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

48

Laver, J., and M. A. S. Moore. "Clinical Use of Recombinant Human Hematopoietic Growth Factors." JNCI Journal of the National Cancer Institute 81, no. 18 (September 20, 1989): 1370–82. http://dx.doi.org/10.1093/jnci/81.18.1370.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

49

Dybko, Jaroslaw, Donata Urbaniak-Kujda, Katarzyna Kapelko-Slowik, and Kazimierz Kuliczkowski. "Coexpression of Bmi-1 and Interleukin-3 Receptor Alpha Chain (CD123) Correlate with Poor Prognosis In Acute Myeloid Leukemia." Blood 116, no. 21 (November 19, 2010): 4324. http://dx.doi.org/10.1182/blood.v116.21.4324.4324.

Texto completo da fonte

Resumo:

Abstract Abstract 4324 Introduction Acute myeloid leukemia (AML) is characterized by the accumulation of immature cells due to disturbed differentiation and proliferation of the myeloid lineage. The traditional AML classification based on morphology, immunophenotyping, and cytogenetic abnormalities is not perfect, in part, because the leukemic population is functionally heterogeneous. AML cells comprise leukemic stem cells (LSCs) and mature leukemia cells that have differentiated abnormally. There has been a recent effort to identify new markers underlying this functional heterogeneity. Bmi-1

Estilos ABNT, Harvard, Vancouver, APA, etc.

50

Ruggeri, Loredana, Elena Urbani, Davide Chiasserini, Federica Susta, Pierluigi Orvietani, Emanuela Burchielli, Dunia Ramarli, et al. "Alloreactive Natural Killer Cells Initiate a Unique Cellular and Molecular Pathway That Greatly Accelerates Immune Reconstitution after Allogeneic Bone Marrow Transplantation." Blood 128, no. 22 (December 2, 2016): 548. http://dx.doi.org/10.1182/blood.v128.22.548.548.

Texto completo da fonte

Resumo:

Abstract One outstanding issue in allogeneic hematopoietic transplantation is impaired immune reconstitution. As the primary site of T cell development, the thymus plays a key role in the generation of a strong yet self-tolerant adaptive immune response, essential in the face of the potential threat from pathogens or neoplasia. Allogeneic hematopoietic transplantation may acutely damage the thymus through the chemo or radiotherapy, antibody therapy of the conditioning regime, infections acquired by the immunosuppressed patient, and thymic graft versus host disease. To date, attempts to improve

Estilos ABNT, Harvard, Vancouver, APA, etc.

Oferecemos descontos em todos os planos premium para autores cujas obras estão incluídas em seleções literárias temáticas. Contate-nos para obter um código promocional único!